DongKoo Bio&Pharma Co. Ltd (006620) - Total Liabilities

Latest as of September 2025: ₩158.34 Billion KRW ≈ $107.31 Million USD

Based on the latest financial reports, DongKoo Bio&Pharma Co. Ltd (006620) has total liabilities worth ₩158.34 Billion KRW (≈ $107.31 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore 006620 cash generation efficiency to assess how effectively this company generates cash.

DongKoo Bio&Pharma Co. Ltd - Total Liabilities Trend (2015–2024)

This chart illustrates how DongKoo Bio&Pharma Co. Ltd's total liabilities have evolved over time, based on quarterly financial data. Check DongKoo Bio&Pharma Co. Ltd (006620) asset resilience to evaluate the company's liquid asset resilience ratio.

DongKoo Bio&Pharma Co. Ltd Competitors by Total Liabilities

The table below lists competitors of DongKoo Bio&Pharma Co. Ltd ranked by their total liabilities.

Company Country Total Liabilities
Western Alaska Minerals Corp
V:WAM
Canada CA$6.35 Million
Anghami De Inc
NASDAQ:ANGH
USA $65.43 Million
Next Entertainment World Co. Ltd
KQ:160550
Korea ₩128.06 Billion
Generations Bancorp NY Inc
NASDAQ:GBNY
USA $322.35 Million
Syntara Ltd
AU:SNT
Australia AU$5.42 Million
Wiseway Group Ltd
AU:WWG
Australia AU$64.78 Million
NGE Capital Ltd
AU:NGE
Australia AU$1.46 Million
Trisula International Tbk
JK:TRIS
Indonesia Rp534.62 Billion

Liability Composition Analysis (2015–2024)

This chart breaks down DongKoo Bio&Pharma Co. Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see DongKoo Bio&Pharma Co. Ltd (006620) market capitalisation.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 0.92 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 1.43 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.59 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how DongKoo Bio&Pharma Co. Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for DongKoo Bio&Pharma Co. Ltd (2015–2024)

The table below shows the annual total liabilities of DongKoo Bio&Pharma Co. Ltd from 2015 to 2024.

Year Total Liabilities Change
2024-12-31 ₩138.73 Billion
≈ $94.01 Million
+72.00%
2023-12-31 ₩80.66 Billion
≈ $54.66 Million
+15.30%
2022-12-31 ₩69.95 Billion
≈ $47.41 Million
+27.97%
2021-12-31 ₩54.66 Billion
≈ $37.04 Million
+9.98%
2020-12-31 ₩49.70 Billion
≈ $33.68 Million
+5.58%
2019-12-31 ₩47.07 Billion
≈ $31.90 Million
+46.28%
2018-12-31 ₩32.18 Billion
≈ $21.81 Million
-14.97%
2017-12-31 ₩37.85 Billion
≈ $25.65 Million
-12.52%
2016-12-31 ₩43.27 Billion
≈ $29.32 Million
-25.69%
2015-12-31 ₩58.22 Billion
≈ $39.46 Million
--

About DongKoo Bio&Pharma Co. Ltd

KQ:006620 Korea Pharmaceuticals
Market Cap
$33.52 Million
₩49.46 Billion KRW
Market Cap Rank
#23351 Global
#1654 in Korea
Share Price
₩5150.00
Change (1 day)
-0.96%
52-Week Range
₩4765.00 - ₩6090.00
All Time High
₩13745.55
About

DongKoo Bio&Pharma. Co., Ltd. researches, develops, manufactures, and sells medicines in South Korea. The company offers prescribed medicines, such as liver disease, skeletal muscle relaxant, endocrine system, brain nervous system, urogenital, antiobestic, digestive system, circulatory organ, allergenic, mental disease, oral dermatology, external preparation of dermatology, antiseptic, antiviral,… Read more